Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A 36-year-old male using dutasteride and minoxidil has seen significant hair regrowth, confirmed by a dermatologist and supported by before-and-after photos. He plans to increase his oral minoxidil dosage and add dermapen to his routine.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

Switching from oral finasteride to topical dutasteride for hair loss, with mixed experiences reported; some users found oral treatments more effective. Combining treatments like dutasteride and minoxidil was also suggested for better results.

A 36-year-old switched from Finasteride to Dutasteride after 6 years due to thinning hair, adding oral Minoxidil for regrowth. Dutasteride improved hair thickness with fewer side effects, while Finasteride caused anxiety and back pain.

The user is concerned about hair loss and is using minoxidil while considering beetroot powder, which may affect testosterone and DHT levels. They are cautious about starting finasteride due to potential side effects.

The user shared a 5-month progress update on hair regrowth using dutasteride (0.5mg), topical minoxidil, and a dermaroller, along with improved diet and scalp care. The user reported significant progress with no adverse side effects.

A new topical treatment, TH07, combining finasteride, latanoprost, and minoxidil, is entering phase III trials with promising early results. Some users express skepticism, noting the treatment uses existing products.

Switching from finasteride to dutasteride can lead to increased shedding and hair loss for some, while others see improvement. The effectiveness varies, with some users experiencing better results with dutasteride, while others find finasteride more beneficial.

PP405 and JXL069 are confirmed to be the same molecule, leading to disappointment due to poor hair regrowth results. Users express skepticism about the credibility of Pelage and the effectiveness of JXL069.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

A 27-year-old male with diffuse hair loss, including the donor area, did not respond to finasteride, dutasteride, or minoxidil. He suspects his hair loss may be linked to a mild connective tissue disorder, possibly affecting the structural support of hair follicles, rather than being purely hormonal.

Suvomipic, previously known as PP405, is progressing to Phase 3 trials for hair loss treatment. Its effectiveness compared to existing treatments like Minoxidil and Finasteride is still uncertain.

A user shared their experience using dutasteride for hair loss, noting subtle improvements and thicker hair without significant regrowth. They did not use finasteride or minoxidil, and experienced occasional shedding but no side effects.

A 31-year-old man has been using Dutasteride since 2022, alongside topical Minoxidil, with positive results and no issues. His new healthcare provider expressed concerns about long-term Dutasteride use and suggested alternatives like oral Minoxidil and Spironolactone, but the patient is hesitant to change a successful routine.

Switching from finasteride to dutasteride worsened hair loss and caused a burning sensation. Users suggest sticking with finasteride, using ketoconazole shampoo, and consulting a dermatologist.

The conversation discusses various hair loss treatments, including finasteride, dutasteride, minoxidil, and topical alternatives, with users sharing personal experiences and concerns about side effects like libido changes. Some users regret delaying treatment due to misinformation, while others report positive results or caution against potential side effects.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.

The user is considering increasing their dose of Dutasteride from 0.5 mg to 2.5 mg while using Minoxidil, DermaRoll, and other treatments for hair regrowth after multiple hair transplants. Many responses suggest accepting baldness or using a hair system instead of continuing with medications.

A new treatment using dermal sheath cup cells may regrow hair and could require repeat treatments every 8 years. Users discuss ongoing trials and plan to use finasteride and minoxidil until the treatment is available.

PP405 is in phase 2 trials for hair loss, with discussions on its cost and effectiveness compared to minoxidil and finasteride. Users are skeptical about its efficacy and timeline, with hopes for market release by 2027.

A user allergic to propylene glycol seeks alternatives for a DIY topical finasteride solution, considering glycerin or glycerol-based vehicles. Another user suggests a recipe using propanediol, DMSO, MCT oil, and peppermint oil, incorporating minoxidil, dutasteride, and finasteride.

A 42-year-old shares progress using finasteride and dutasteride for 9 months, with occasional minoxidil use, noticing results after a month. The user applied minoxidil consistently for 3 months, then sporadically once a week.

The conversation discusses an experiment involving hair loss treatments, including the use of Verteporfin, KY19382, dutasteride, oral and topical minoxidil, AHK-Cu, and microneedling. The experiment aims to test the effectiveness of these treatments in promoting hair growth and healing without scarring, with updates planned every few months.

The conversation is about purchasing dutasteride capsules from India and concerns about high temperatures affecting their efficacy. Users suggest that medicines are stored in cool conditions and recommend gel capsules over tablets.

The conversation discusses hair loss treatment options, focusing on finasteride and its potential effects on gynecomastia. The user is considering finasteride while managing hormone levels with supplements like boron, vitamin D, zinc, magnesium, and P5P, and is advised to consult an endocrinologist for further evaluation.

Topical dutasteride 0.05% is reported to outperform oral finasteride with minimal side effects, but concerns about study bias exist due to company funding. Some users report mixed results with topical dutasteride, noting issues with skin penetration and systemic absorption.

The user shared progress pictures showing hair improvement since July 2025 using a combo pill containing oral minoxidil 5mg, finasteride 1.1mg, and biotin 1mg, with no noticeable side effects. The user feels more confident and has not experienced any shedding.

Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.

The post and conversation are about a user's 6-month hair loss progress using 0.5 mg dutasteride daily and 2.5 mg oral minoxidil daily. Users congratulate the progress and discuss the effectiveness of the treatment.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.